K-V gets permanent CEO

> K-V Pharmaceutical, which has faced a number of challenges over the past couple of years, has tapped Greg Divis as its permanent CEO.  He had served as interim CEO since June and will continue to serve as president of Ther-Rx, the branded pharmaceutical subsidiary of the company. Report

> Topaz Pharmaceuticals has appointed Bob Radie as president and CEO. Thomas Beck, who was serving as interim CEO, will resume his role as chief medical officer of the company.

> Jai Nagarkatti, Sigma-Aldrich's chairman, president and CEO, has passed away. The company's board has had a succession plan for key officers, including the CEO. The board has elected Rakesh Sachdev, who most recently served as CFO, chief administrative officer, and senior VP of the International business, as president and CEO. The board also has elected Barrett Toan as chairman as of Nov. 14. Sigma-Aldrich release

> Palatin Technologies has appointed Jeffrey Edelson as CMO. Palatin release

> On-Q-ity has tapped Walter Carney as its new chief scientific officer. On-Q-ity release

> Affymax has announced that Herb Cross has joined the company as chief accounting officer and vice president of Finance. Affymax release

> Omeros has named Kenneth Ferguson  to the position of VP, development. Omeros release

> Catalyst Pharmaceutical Partners has announced that Richard Silverman has joined its scientific advisory board. Silverman is the inventor of Pfizer's $3 billion pain medication, Lyrica. Catalyst release

> Entest BioMedical has added Gregory McDonald to its scientific advisory board. The company views this as a major step in moving forward with its immuno-therapeutic cancer vaccine for dogs, as McDonald is a practicing veterinarian and typically treats more than 700 dogs per year that have various forms of cancer. Entest release

> Dutch biotechnology company Mucosis B.V. has elected Barry Buckland to its supervisory board. Mucosis release

> Jennerex has announced that Barry Sherman has been elected to the company's board of directors. Jennerex release

> Regeneron Pharmaceuticals has elected Christine Poon to fill a new seat on its expanded board of directors. She was formerly vice chairman of the board of directors of Johnson & Johnson and Worldwide Chairman of the Johnson & Johnson Pharmaceuticals Group. Regeneron release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.